Answering the Unmet Medical Need in Primary Billiary Cholangitis (PBC)

We are delighted to welcome you to this Industry sponsored symposium focusing on alleviating the individual and population wide needs associated with primary biliary cholangitis (formerly known as primary biliary cirrhosis; PBC).

With Obeticholic acid (Intercept Pharmaceuticals) approaching approval for patients with PBC, the therapeutic landscape is likely to evolve significantly, alongside notable renewed interest in PBC generally, with the UK-PBC consortium as you know, being very active nationally in driving basic and applied translational science for patient benefit.

PBC remains an important liver disease: 1 in 1000 women over the age of 40 live with disease, in which autoimmune biliary injury drives a chronic, and ductopenic, cholestatic liver injury. Untreated disease or disease unresponsive to the only presently licenced therapy, Ursodeoxycholic acid, progresses to end stage liver disease and all the attendant complications. Accompanying the chronic liver injury are frequent symptomatic complaints for patients associated with impairments in quality of life from pruritus and fatigue.

This programme with an expert faculty, will present an overview of the state of the art in PBC therapeutics, with an emphasis on the need for early diagnosis, relevant clinical endpoints and emerging treatment options targeted to pathogenic mechanisms. The presentations have been designed to increase the knowledge, competence and practice performance of clinicians who care for patients with PBC.

We naturally look forward to meeting you at this exciting morning Industry sponsored symposium, which we are confident will prove to be of interest and broad educational interest.

Dr. Stephen Ryder
Prof. Gideon Hirschfeld

DOWNLOADS

Event Flyer PDF 1.05Mb